跳至主要内容
临床试验/NCT05205967
NCT05205967进行中(未招募)不适用

REFLECTION: Real World Evidence for Learnings in Early Cancer Detection, a Clinical Practice Learning Program for Galleri®

GRAIL, Inc.15 个研究点 分布在 1 个国家目标入组 14,633 人开始时间: 2021年8月23日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
GRAIL, Inc.
入组人数
14,633
试验地点
15
主要终点
To describe signal detection and cancer detection within and across sites among participants who opt to receive Galleri® in a real world setting.

研究概览

简要总结

REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 14,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in routine clinical settings. The purpose of the study is to understand the real-world experience of Galleri® in clinical settings.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Participant has the ability to understand and the willingness to sign a written informed consent form (ICF);
  • Participant is at least 22 years old at the time of consent;
  • A provider or their designee has ordered the Galleri® test; and
  • Participant has the ability to comprehend the participant questionnaires.

排除标准

  • There are no exclusions

结局指标

主要结局

To describe signal detection and cancer detection within and across sites among participants who opt to receive Galleri® in a real world setting.

时间窗: Up to 12 Months

次要结局

  • Galleri®: To assess the feasibility and acceptability of Galleri® from the perspective of participants and patient-reported outcomes (PROs) in a real-world setting.(Up to 12 Months)
  • HCRU: To assess healthcare resource utilization (HCRU) associated with cancer diagnostic workups for participants with signal detected Galleri® test results.(Up to 12 Months)

研究者

发起方
GRAIL, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (15)

Loading locations...

相似试验